Hereditäre Mamma- und Genitalkarzinome

K. Rhiem; R. K. Schmutzler

doi:10.1055/s-0031-1283842

Lege artis - Das Magazin zur ärztlichen Weiterbildung, Inhaltsverzeichnis

Frauenheilkunde up2date 2011; 5(06): 369-380
DOI: 10.1055/s-0031-1283842

Allgemeine Gynäkologie und gynäkologische Onkologie

Hereditäre Mamma- und Genitalkarzinome

Autor*innen

K. Rhiem
R. K. Schmutzler

Abstract

Volltext

Referenzen

Literatur
1 Robert-Koch-Institut und die Gesellschaft der epidemiologischen Krebsregister in Deutschland e. V.. Krebs in Deutschland 2005 / 2006. Häufigkeiten und Trends. Berlin: 2010 7.. Aufl.
2 Miki Y, Swensen J, Shattuck-Eidens D et al. A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science 1994; 266: 66-71
3 Wooster R, Bignell G, Lancaster J et al. Identification of the breast cancer susceptibility gene BRCA2. Nature 1995; 378: 789-792
4 Walsh T, Lee MK, Casadei S et al. Detection of inherited mutations for breast and ovarian cancer using genomic capture and massively parallel sequencing. Proc Natl Acad Sci USA 2010; 107: 12629-12633
5 Gruber SB, Thompson WD. Cancer and Steroid Hormone Study Group. A population-based study of endometrial cancer and familial risk in younger women. Cancer Epidemiol Biomarkers Prev 1996; 5: 411-417
6 Schmutzler RK, Löffler M, Windeler J et al. Familiärer Brust- und Eierstockkrebs: Von der Forschung zur Regelversorgung. Dtsch Arztebl 2005; 102: A3486 / B-2948 / C-2461
7 Meindl A, Ditsch N, Kast K et al. Hereditary breast and ovarian cancer: new genes, new treatments, new concepts. Dtsch Arztebl Int 2011; 108: 323-330
8 Muller A, Beckmann C, Westphal G et al. German HNPCC Consortium, Prevalence of the mismatch-repair-deficient phenotype in colonic adenomas arising in HNPCC patients: results of a 5-year follow-up study. Int J Colorectal Dis 2006; 21: 632-641
9 King MC, Marks JH, Mandell JB. Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2. Science 2003; 302: 643-646
10 Meindl A, Hellebrand H, Wiek C et al. Germline mutations in breast and ovarian cancer pedigrees establish RAD51C as a human cancer susceptibility gene. Nat Genet 2010; 42: 410-414
11 Levy-Lahad E. Fanconi anemia and breast cancer susceptibility meet again. Nat Genet 2010; 42: 368-369
12 Weischer M, Bojesen SE, Ellervik C et al. CHEK2*1100delC genotyping for clinical assessment of breast cancer risk: meta-analyses of 26 000 patient cases and 27 000 controls. J Clin Oncol 2008; 26: 542-548
13 Dufault MR, Betz B, Wappenschmidt B et al. Limited relevance of the CHEK2 gene in hereditary breast cancer. Int J Cancer 2004; 110: 320-325
14 Turnbull C, Rahman N. Genetic predisposition to breast cancer: past, present, and future. Annu Rev Genomics Hum Genet 2008; 9: 321-345
15 Easton DF, Pooley KA, Dunning AM et al. Genome-wide association study identifies novel breast cancer susceptibility loci. Nature 2007; 447: 1087-1093
16 Hampel H, Frankel W, Panescu J et al. Screening for Lynch syndrome (hereditary nonpolyposis colorectal cancer) among endometrial cancer patients. Cancer Res 2006; 66: 7810-7817
17 Ollikainen M, Abdel-Rahman WM, Moisio AL et al. Molecular analysis of familial endometrial carcinoma: a manifestation of hereditary nonpolyposis colorectal cancer or a separate syndrome?. J Clin Oncol 2005; 23: 4609-4616
18 Goodfellow PJ, Buttin BM, Herzog TJ et al. Prevalence of defective DNA mismatch repair and MSH6 mutation in an unselected series of endometrial cancers. Proc Natl Acad Sci USA 2003; 100: 5908-5913
19 Woods MO, Williams P, Careen A et al. A new variant database for mismatch repair genes associated with Lynch syndrome. Hum Mutat 2007; 28: 669-673
20 Peltomaki P. Lynch syndrome genes. Fam Cancer 2005; 4: 227-232
21 Lu KH, Schorge JO, Rodabaugh KJ et al. Prospective determination of prevalence of Lynch syndrome in young women with endometrial cancer. J Clin Oncol 2001; K25: 5158-5164
22 Malander S, Rabech E, Kristoffersson U et al. The contribution of the hereditary nonpolyposis colorectal cancer syndrome to the development of ovarian cancer. Gynecol Oncol 2006; 101: 238-243
23 Vasen HF, Watson P, Mecklin JP et al. New clinical critieria for hereditary nonpolyposis colorectal cancer (HNPCC, Lynch syndrome) proposed by the International Collaborative group on HNPCC. Gastroenterol 1999; 116: 1453-1456
24 Umar A, Boland CR, Terdiman JP et al. Revised Bethesda Guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability. J Natl Cancer Inst 2004; 96: 261-268
25 Hemminki K, Dong C, Vaittinin P. Familial risks in cervical cancer: is there a hereditary component?. Int J Cancer 1999; 82: 775-781
26 Hussain SK, Sundquist J, Hemminki K. Familial clustering of cancer at human papillomavirus-associated sites according to the Swedish Family-Cancer Database. Int J Cancer 2008; 122: 1873-1878
27 Lakhani SR, Reis-Filho JS, Fulford L et al. Prediction of BRCA1status in patients with breast cancer using estrogen receptor and basal phenotype. Clin Cancer Res 2005; 11: 5175-5180
28 Dent R, Trudeau M, Pritchard KI et al. Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res 2007; 13: 4429-4434
29 Turner NC, Reis-Filho JS. Basal-like breast cancer and the BRCA1 phenotype. Oncogene 2006; 25: 5846-5853
30 Honrado E, Benitez J, Palacios J. The molecular pathology of hereditary breast cancer: Genetic testing and therapeutic implications. Mod Pathol 2005; 18: 1305-1320
31 Foulkes WD, Stefansson IM, Chappuis PO et al. Germline BRCA1 mutations and a basal epithelial phenotype in breast cancer. J Natl Cancer Inst 2003; 95: 1482-1485
32 Schmutzler RK, Rhiem K, Breuer P et al. Outcome of a structured surveillance programme in women with a familial predisposition for breast cancer. Eur J Cancer Prev 2006; 15: 483-489
33 Heywang-Köbrunner SH, Schreer I, Heindel W et al. Imaging studies for the early detection of breast cancer. Dtsch Arztebl 2008; 105: 541-547
34 Rhiem K, Flucke U, Schmutzler RK. BRCA1-associated Breast carcinomas frequently present with benign sonographic features. Am J Roentgenol 2006; 185: E11-E12
35 Bosse K, Rhiem K, Wappenschmidt B et al. Screening for ovarian cancer by transvaginal ultrasound and serum CA125 measurement in women with a familial predisposition: a prospective cohort study. Gynecol Oncol 2006; 103: 1077-1082
36 Graeser MK, Engel C, Rhiem K et al. Contralateral breast cancer risk in BRCA1 and BRCA2 mutation carriers. J Clin Oncol 2009; 27: 5887-5892
37 Tilanus-Linthorst MM, Alves C, Seynaeve C et al. Contralateral recurrence and prognostic factors in familial non-BRCA1 / 2-associated breast cancer. Br J Surg 2006; 93: 961-968
38 Kauff ND, Domchek SM, Friebel TM et al. Risk-reducing salpingo-oophorectomy for the prevention of BRCA1- and BRCA2-associated breast and gynecologic cancer: a multicenter, prospective study. J Clin Oncol 2008; 26: 1331-1337
39 Metcalfe KA, Lubinski J, Ghadirian P et al. Predictors of contra-lateral prophylactic mastectomy in women with a BRCA1 or BRCA2 mutation: The Hereditary Breast Cancer Clinical Study Group. J Clin Oncol 2008; 26: 1093-1097
40 Rebbeck TR, Friebel T, Lynch HAT. The PROSE Study Group. Bilateral prophylactic mastectomy reduces breast cancer risk in BRCA1 and BRCA2 mutation carriers. J Clin Oncol 2004; 22: 1055-1062
41 Domchek SM, Friebel TM, Singer CF et al. Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality. J Am Med Assoc 2010; 304: 967-975
42 Byrski T, Gronwald J, Huzarski T et al. Pathologic complete response rates in young women with BRCA1-positive breast cancers after neoadjuvant chemotherapy. J Clin Oncol 2010; 28: 375-379
43 Byrski T, Huzarski T, Dent R et al. Response to neoadjuvant therapy with cisplatin in BRCA1-positive breast cancer patients. Breast Cancer Res Treat 2009; 115: 359-363
44 Silver DP, Richardson AL, Eklund AC et al. Efficacy of neoadjuvant Cisplatin in triple-negative breast cancer. J Clin Oncol 2010; 28: 1145-1153
45 Lafarge S, Sylvain V, Ferrara M et al. Inhibition of BRCA1 leads to increased chemoresistance to microtubule-interfering agents, an effect that involves the JNK pathway. Oncogene 2001; 20: 6597-6606
46 Quinn JE, Kennedy RD, Mullan P et al. BRCA1 functions as a differential modulator of chemotherapy-induced apoptosis. Cancer Res 2003; 63: 6221-6228
47 Helleday T. The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings. Mol Oncol 2011; 5: 387-393
48 Stoffel E, Mukherjee B, Raymond VM et al. Calculation of risk of colorectal and endometrial cancer among patients with Lynch syndrome. Gastroenterol 2009; 137: 1621-1627
49 Aarnio M, Sankila R, Pukkala E et al. Cancer risk in mutation carriers of DNA-mismatch-repair genes. Int J Cancer 1999; 81: 214-218
50 Vasen HF, Wijnen JT, Menko FH et al. Cancer risk in families with hereditary nonpolyposis colorectal cancer diagnosed by mutation analysis. Gastroenterol 1996; 110: 1020-1027
51 Walsh MD, Buchanan DD, Cummings MC et al. Lynch syndrome-associated breast cancers: clinicopathologic characteristics of a case series from the colon cancer family registry. Clin Cancer Res 2010; 16: 2214-2224
52 Barrow E, Robinson L, Alduaij W et al. Cumulative lifetime incidence of extracolonic cancers in Lynch syndrome: a report of 121 families with proven mutations. Clin Genet 2009; 75: 141-149
53 Watson P, Butzow R, Lynch HT et al. The clinical features of ovarian cancer in hereditary nonpolyposis colorectal cancer. Gynecol Oncol 2001; 82: 223-228
54 Watson P, Lin KM, Rodriguez-Bigas MA et al. Colorectal carcinoma survival among hereditary nonpolyposis colorectal carcinoma family members. Cancer 1998; 83: 259-266
55 Boks DE, Trujillo AP, Voogd AC et al. Survival analysis of endometrial carcinoma associated with hereditary nonpolyposis colorectal cancer. Int J Cancer 2002; 102: 198-200
56 Manchanda R, Menon U, Michaelson-Cohen R et al. Hereditary non-polyposis colorectal cancer or Lynch syndrome: the gynecological perspective. Curr Opin Ostet Gynecol 2009; 21: 31-38
57 Lu KH, Dinh M, Kohlmann W et al. Gynecologic cancer as a sentinel cancer for women with hereditary nonpolyposis colorectal cancer syndrome. Obstet Gynecol 2005; 105: 569-574
58 Jarvinen HJ, Aarnio M, Mustonen H et al. Controlled 15-year trial on screening for colorectal cancer in families with hereditary nonpolyposis colorectal cancer. Gastroenterol 2000; 118: 829-834
59 Schmeler KM, Lynch HT, Chen LM et al. Prophylactic surgery to reduce the risk of gynecologic cancers in the Lynch syndrome. N Engl J Med 2006; 354: 261-269
60 Lindor NM, Petersen GM, Hadley DW et al. Recommendations for the care of individuals with an inherited predisposition to Lynch syndrome: a systematic review. J Am Med Assoc 2006; 296: 1507-1517